Yourgene Health Share Discussion Threads

[dj trading] 02/12/2019 13:38

Cashburn summary (Cash movement adj for Financing and Business Investment)

YE...Rev Cashburn
2016 2.5 8.2
2017 3.1 7.9
2018 6.1 10.2 (inc Yourgene)
2019 8.9 4.6

1H20 7.8 2.35 (6m and inc Elucigene)

Cash balance 4.1m
dyor

[scrutable] 02/12/2019 12:53

An inspiring report after the drag of a long debilitating litigation.

The acquisition seems to have been an elegant stroke of management

YGen is now at the very top of any UK list of high organic growth companies - currently an astonishing 120%p/a in international markets, to be augmented by the first efforts in the USA. Numerically challenged investors may still be waiting to discern the rapidly increasing margin in the FY results and beyond.

A year from now, cost cutting and additional margin from huge growth in each of all four strategically defined buiness sectors will become even more highly visible and an investor's dream.

[swiftnick] 02/12/2019 12:40

Frenchfry,Yes, frustrating that admin expenses are still higher than gross profits. However, the 22% increase to GBP5.5m (H1 2018-19: GBP4.5m) needs to be viewed in the context of a much higher 97% increase in revenue and also reflects the merger with Elucigene Diagnostics.The report pre-empts your question by saying that the Directors have assessed the company's cost structure as part of the strategic planning process and continue to implement cost reduction measures where appropriate, e.g. during the integration of Elucigene, and I am reassured by the statement that there is an ongoing commitment to keep costs and working capital under control so that increasing gross profits can drive positive cash flows.

[frenchfry] 02/12/2019 08:32

nimbo1 - perhaps you would be so kind to enquire into the growing general admin.expenses, what measures and to what extent the figure will be tackled. Oh and the small army of directors maybe due a streamline?
Thanks in advance.

[schloberts] 02/12/2019 08:28

I’d like to understand the timeframe for the launch of the Illumina NIPT test please.

Some months ago they were saying launch early 2020, which to me means Jan/Feb, but now it won’t be submitted to the regulators until early 2020.

Has there been a delay? How long does regulatory approval take on average?

Thanks

[nimbo1] 02/12/2019 08:14

Anyone else going to investor presentation later? I am any questions you want asked let me know.

I want to understand operational gearing - ie do costs ramp up significantly with illumina distribution.

And competitive landscape.

[timojelly] 02/12/2019 07:27

Momentum players may join in though.

[cottoner] 02/12/2019 07:26

Very positive Outlook statement from today's results.

I am delighted with the transformation of the business and that the strong foundation we've established for delivering rapid growth is already delivering results. At this interim stage we are firmly on target to deliver full year results in-line with market expectations, with consensus analyst forecasts looking for revenues of nearly £17m for the year ending 31 March 2020, a considerable jump from last year's £8.9m.

I am very excited about the significant opportunity ahead of us. We have first-class products that are leading the way in the growing genetic testing market. Our IONA® test has strong reputation for reliability and accuracy and was the first CE marked NIPT product for the European Market. We are also in a position to offer our test across all sequencing platforms and we believe that the launch of the IONA® test on the Illumina platform will be a strong driver of growth next year.

We have established a significant commercial footprint and now sell into 60 territories and we are certain that we will quickly benefit from selling a wider range of products into a wider range of markets, and this in turn will be reflected in further shareholder value creation. We also expect to leverage our strong technical capabilities to develop more content, offering additional products and services to more customers as the adoption of genetic testing becomes more widespread.

We remain confident in our outlook for the year end and very excited about the prospects for further growth over the following years.

[timojelly] 02/12/2019 07:24

There was a big hint of sarcasm in there twix.. All in good time... Seen may an expectation dashed.. Aka since VIY.

[twix386] 02/12/2019 07:21

Getting carried away! That would be lovely and unlikely. Should be a good day though.

[jestercat2] 02/12/2019 07:12

Looking good folks

[timojelly] 02/12/2019 07:05

Time for a rocket? Release the hounds! Well done

[mhw28865] 02/12/2019 07:05

"I am delighted to announce our first EBITDA profit as a demonstration of the transformation that is underway at Yourgene and resultant organic growth, supported by the contribution from Elucigene and the smooth integration process that is almost complete.

"The reorientation of the business to focus on our key four strategic growth drivers is starting to bear fruit, and I remain convinced we have a very significant opportunity ahead of us. We are confident in our outlook for the year end and very excited about the prospects for further growth over the following years."

[cottoner] 30/11/2019 12:34

On the other hand chartists will be keeping a close eye on YGEN.

If it gets to 14p and holds it will have breached a major resistance point, which would become a support and could result in a sustained rise for the share price

It could well depend on how the half-year results and more importantly the forward looking statement is viewed on Monday.

[the monkster] 30/11/2019 01:08

might get to 14 in about 10 years' time. I'll be dead b4 I get half my money back at this rate.

[twix386] 29/11/2019 11:18

Whey-hey!And....https://bionow.co.uk/news/b5ddfadcd2cb62/diagnosis-companies-triumph-at-the-bionow-awardsBig winners on the night included Yourgene Health, a molecular diagnostics group which develops and commercialises genetic products and services. It scooped both the Bionow Company of the Year and the Bionow Investment Deal of the Year Award. The group works in partnership with global leaders in DNA technology to advance diagnostic science. Headquartered in Manchester, Yourgene Health launched its first oncology product, the Elucigene DPYD assay, this year as it looks to broaden its offering within precision medicine.Bionow Investment Deal of the Year Sponsored by QIAGENWinner: Yourgene HealthDeal: Acquisition of Elucigene a Manchester-based molecular diagnostics manufacturer and developer by Yourgene Health plc

[jonnycj] 29/11/2019 10:59

Looks like the Twix Indicator has moved through the 50 level !

[mhw28865] 29/11/2019 10:42

Hope your right twix sick and tired of being stuck in the 11_13range

[twix386] 29/11/2019 09:51

Can see share price rising by c.o.b. today.Anyone already thinking of buying shouldn't wait imv.Just my expectation which remembering this is Yourgene has to come with no money back guarantee. lol

[hjb1] 28/11/2019 13:53

might never come to market.There must be plenty trying and in research faze never to see the light of day.

[cottoner] 28/11/2019 13:04

Well , if there wasn't a market there wouldn't be competition.

Better a thriving market and competition IMO.

Pepsi and Coca Cola seemed to do ok. :-)

[gnnmartin] 28/11/2019 12:59

Interesting, Twix. To save others the effort of identifying the source, that comes from

It's hard to know whether this is good or bad for Yourgene. The interest in NIPT and within governments for promoting NIPT is obviously good, but the increasing well funded competition is bad. Is the Thermo Fisher "liquid chromatography-mass spectrometry testing platform" the platform on which Yourgene tests are run, or is it a competing technology?

[mhw28865] 22/11/2019 09:05

Nice one nimbo good luck